Loading clinical trials...
Loading clinical trials...
Single-center, Open-label, Single-arm Clinical Study of Efficacy and Safety of Anti-CD123 CAR-T Therapy in Patients With Refractory/Relapsed CD123+ Acute Myeloid Leukemia.
Conditions
Interventions
Third-generation anti-CD123 CAR-T cells
Locations
1
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
July 6, 2019
Primary Completion Date
July 1, 2021
Completion Date
July 1, 2022
Last Updated
August 7, 2019
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions